| Literature DB >> 31996792 |
Alexandros Spyridonidis1, Myriam Labopin2, Bipin N Savani3, Riitta Niittyvuopio4, Didier Blaise5, Charles Craddock6, Gerard Socié7, Uwe Platzbecker8, Dietrich Beelen9, Noel Milpied10, Jan J Cornelissen11, Arnold Ganser12, Anne Huynh13, Laimonas Griskevicius14, Sebastian Giebel15, Mahmoud Aljurf16, Eolia Brissot2, Florent Malard2, Jordi Esteve17, Zinaida Peric18, Frédéric Baron19, Annalisa Ruggeri20, Christoph Schmid21, Maria Gilleece22, Norbert-Claude Gorin2, Francesco Lanza23, Roni Shouval24, Jurjen Versluis12, Gesine Bug25, Yngvar Fløisand26, Fabio Ciceri27, Jamie Sanz28, Ali Bazarbachi29, Arnon Nagler30, Mohamad Mohty2.
Abstract
To address limitations of the currently used reduced-intensity/myeloablative conditioning (RIC/MAC) classification scheme we aimed to develop a tool that can capture more standardized the conditioning intensity of allogeneic hematopoietic cell transplantation (HCT). We assigned intensity weight scores for frequently used conditioning regimen components and used their sum to generate the transplant conditioning intensity (TCI) score. We retrospectively tested the impact of TCI on 8255 adult (45-65 years) acute myeloid leukemia patients who underwent HCT in first complete remission. A Cox model for early nonrelapse mortality (NRM) yielded a 3-group TCI risk scheme (low, intermediate, high) with respective TCI scores of [1-2], [2.5-3.5] and [4-6]. On multivariate modeling, TCI grouping was highly and better predictive for early (day 100 and 180) NRM, 2-year NRM and relapse (REL) as compared with the RIC/MAC classification. Validation was done on 200 bootstrap samples. Moreover, TCI scoring enabled the identification of a distinct subgroup of RIC and MAC conditioning regimens with an intermediate TCI [2.5-3.5] score that had identical outcomes and which are frequently referred as "reduced toxicity conditioning". TCI scheme provides an improvement of the RIC/MAC classification. We propose TCI as a new tool to define and measure the conditioning regimen intensity.Entities:
Mesh:
Year: 2020 PMID: 31996792 DOI: 10.1038/s41409-020-0803-y
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483